Shares of CVRx, Inc. (NASDAQ:CVRX – Get Free Report) have been given a consensus rating of “Hold” by the seven research firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $2.70.
A number of research analysts have recently commented on CVRX shares. Weiss Ratings restated a “sell (e+)” rating on shares of CVRx in a research note on Friday, October 30th. Lake Street Capital dropped their price target on CVRx from $3.50 to $1.50 and set a “hold” rating on the stock in a research report on Friday, November 6th. Canaccord Genuity Group downgraded CVRx from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $5.00 to $2.00 in a report on Friday, November 6th. William Blair lowered CVRx from an “outperform” rating to a “market perform” rating in a research report on Friday, November 6th. Finally, Craig Hallum downgraded CVRx from a “buy” rating to a “hold” rating and set a $4.00 price target on the stock. in a research note on Friday, August 7th.
Get Our Latest Analysis on CVRx
Institutional Inflows and Outflows
Key CVRx News
Investors following CVRX have been watching these news items:
- Negative Sentiment: The lawsuit alleges CVRx misled investors between July 25, 2023, and August 6, 2026. Reports cite alleged kickbacks involving its Barostim heart-failure device and a federal False Claims Act probe, alongside a guidance cut attributed to weak sales-force productivity. These are allegations, not proven findings. Article
- Negative Sentiment: Several firms reiterated the class action and urged eligible investors to seek lead-plaintiff status by January 8, 2027. Repeated litigation notices may keep legal and reputational risks in focus, though they are largely reminders rather than separate developments. Article
CVRx Stock Down 11.8%
Shares of NASDAQ CVRX opened at $0.53 on Friday. The company has a market cap of $15.18 million, a price-to-earnings ratio of -0.27 and a beta of 0.81. The firm’s fifty day moving average is $1.66 and its 200 day moving average is $4.87. The company has a quick ratio of 5.71, a current ratio of 6.80 and a debt-to-equity ratio of 4.24. CVRx has a 52 week low of $0.53 and a 52 week high of $10.28.
CVRx (NASDAQ:CVRX – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.02). CVRx had a negative return on equity of 208.45% and a negative net margin of 88.28%. The business had revenue of $13.83 million during the quarter, compared to analysts’ expectations of $13.93 million. On average, equities research analysts expect that CVRx will post -2.05 earnings per share for the current year.
CVRx Company Profile
CVRx, Inc. is a medical technology company that develops and commercializes implantable neuromodulation devices for cardiovascular conditions. Its technology is designed to influence the autonomic nervous system, which helps regulate functions such as heart rate and blood pressure. The company’s primary product is Barostim, an implantable system that delivers electrical signals to baroreceptors in the carotid artery. In the United States, Barostim is approved to improve symptoms for certain patients with heart failure who remain symptomatic despite medical therapy.
Featured Stories
- Five stocks we like better than CVRx
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.
